SB227
Cap cost sharing for prescription insulin drugs
📋 What This Bill Does
The bill caps cost sharing for prescription insulin drugs at thirty-five dollars per thirty-day supply for health plans issued or renewed after the effective date. This applies to all covered prescription insulin drugs used to treat diabetes. No penalties or exceptions are specified.
Plain English summary · Non-partisan · Auto-generated
Rationale
The bill imposes a government mandate on health plans regarding pricing for insulin, which conflicts with the Libertarian principles of free markets and minimal government intervention in economic matters.
Risks and Concerns
- Increased government control over healthcare pricing
- Potential for reduced competition in the insulin market
- Encouragement of further government intervention in healthcare
Platform Citations (2)
2.1 Aggression, Property, and Contract
OPPOSES
The bill mandates pricing, infringing on free market principles.
free_markets
OPPOSES
The bill contradicts the LPO's stance against government-imposed pricing.